Ignite Creation Date:
2025-12-25 @ 2:12 AM
Ignite Modification Date:
2026-03-13 @ 2:35 PM
Study NCT ID:
NCT06541860
Status:
RECRUITING
Last Update Posted:
2024-08-07
First Post:
2024-04-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
DAratumumab and REvlimid REfractory MM
Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-21
Start Date Type:
ACTUAL
Primary Completion Date:
2028-02-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08-21
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-09
First Submit QC Date:
None
Study First Post Date:
2024-08-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-02
Last Update Post Date:
2024-08-07
Last Update Post Date Type:
ACTUAL